Literature DB >> 11305921

Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides.

L Zhang1, L Song, G Terracina, Y Liu, B Pramanik, E Parker.   

Abstract

Recent studies of gamma-secretase have pointed out that it may be comprised of a multisubunit complex with presenilin 1 and presenilin 2 as central components. Elucidation of the biochemical mechanism of this enzymatic activity will provide important information for developing gamma-secretase inhibitors in Alzheimer's disease therapy. Here we describe the biochemical characterization of gamma-secretase activities using a sensitive, membrane-based assay system. Membranes were isolated from 293 cells expressing C99, the substrate of gamma-secretase. Upon incubation at 37 degrees C, C99 is cleaved by the endogenous gamma-secretase, and Abeta peptides are liberated. Abeta40 and Abeta42 gamma-secretase activities are very similar in terms of their kinetic profiles and pH dependence, supporting the notion that a single enzyme is involved in both Abeta40 and Abeta42 production. Pepstatin A inhibited Abeta40 and Abeta42 gamma-secretase activities with similar potency. Peptide difluoroketone and peptide aldehyde inhibitors inhibited Abeta40 production in a dose-dependent fashion, enhanced Abeta42 production at low concentrations, and inhibited Abeta42 production at high concentrations. Although the selective increase of Abeta42 by low concentrations of peptide difluoroketone and peptide aldehyde inhibitors has been reported in intact cells, the finding that this phenomenon occurs in a membrane-based assay system suggests that these compounds increase Abeta42 by a direct effect on gamma-secretase. The ability of these compounds to increase Abeta42 production may reflect allosteric modulation of the gamma-secretase complex by a mechanism related to that responsible for the increase of Abeta42 production by mutations in presenilins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11305921     DOI: 10.1021/bi0028800

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  18 in total

Review 1.  Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

Authors:  C Dingwall
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

3.  Discovery of SCH 900229, a Potent Presenilin 1 Selective γ-Secretase Inhibitor for the Treatment of Alzheimer's Disease.

Authors:  Wen-Lian Wu; Martin Domalski; Duane A Burnett; Hubert Josien; Thomas Bara; Murali Rajagopalan; Ruo Xu; John Clader; William J Greenlee; Andrew Brunskill; Lynn A Hyde; Robert A Del Vecchio; Mary E Cohen-Williams; Lixin Song; Julie Lee; Giuseppe Terracina; Qi Zhang; Amin Nomeir; Eric M Parker; Lili Zhang
Journal:  ACS Med Chem Lett       Date:  2012-04-09       Impact factor: 4.345

Review 4.  The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism.

Authors:  Jie Shen; Raymond J Kelleher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-29       Impact factor: 11.205

5.  PS1 N- and C-terminal fragments form a complex that functions in APP processing and Notch signaling.

Authors:  D Levitan; J Lee; L Song; R Manning; G Wong; E Parker; L Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

6.  A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity.

Authors:  Elizabeth A Heilig; Weiming Xia; Jie Shen; Raymond J Kelleher
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

7.  A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis.

Authors:  Eric H Schroeter; Ma Xenia G Ilagan; Anne L Brunkan; Silva Hecimovic; Yue-ming Li; Min Xu; Huw D Lewis; Meera T Saxena; Bart De Strooper; Archie Coonrod; Taisuke Tomita; Takeshi Iwatsubo; Chad L Moore; Alison Goate; Michael S Wolfe; Mark Shearman; Raphael Kopan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

8.  Trans-dominant negative effects of pathogenic PSEN1 mutations on γ-secretase activity and Aβ production.

Authors:  Elizabeth A Heilig; Usha Gutti; Tara Tai; Jie Shen; Raymond J Kelleher
Journal:  J Neurosci       Date:  2013-07-10       Impact factor: 6.167

Review 9.  Endocytosis and intracellular trafficking of Notch and its ligands.

Authors:  Shinya Yamamoto; Wu-Lin Charng; Hugo J Bellen
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

10.  In Vivo Characterization of a Novel γ-Secretase Inhibitor SCH 697466 in Rodents and Investigation of Strategies for Managing Notch-Related Side Effects.

Authors:  Lynn A Hyde; Qi Zhang; Robert A Del Vecchio; Prescott T Leach; Mary E Cohen-Williams; Lei Chen; Gwendolyn T Wong; Nansie A McHugh; Joseph Chen; Guy A Higgins; Theodros Asberom; Wei Li; Dmitri Pissarnitski; Diane Levitan; Amin A Nomeir; John W Clader; Lili Zhang; Eric M Parker
Journal:  Int J Alzheimers Dis       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.